Edvince AB was granted FDA Orphan-Drug Designation for EDV2209 in treatment of subarachnoid hemorrhage

Edvince AB, a biotech company that is developing a new treatment concept to minimize brain damage subsequent to cerebral ischemia, received a positive response from the US Food and Drug Administration (FDA) on august 3rd, granting the EDV2209 drug orphan-drug designation for treatment of subarachnoid hemorrhage.Orphan-drug designation can in the USA be granted for treatments targeting diseases with less than 200,000 patients yearly. Orphan-drug designation status for a drug is valuable, and comes with many developmental and market benefits. For example, development cost tax incentives and